NCT07313670

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 122 (estimated)
• Sponsor: Muhammad Aamir Latif · Academic / Other
• Sex: All
• Age: 2 Months – 12 Years
• Healthy volunteers: Not accepted

Summary

Although, hydrocortisone has shown promise in managing refractory shock, its role in early septic shock management remains unclear. This study aims to provide robust evidence on the clinical and hemodynamic outcomes of early hydrocortisone use in pediatric septic shock, contributing to standardized treatment protocols and improved survival rates.

Detailed description

Despite global advancements in pediatric critical care, mortality and morbidity in septic shock remain unacceptably high. Although data suggest a reduction in mortality with steroid therapy in refractory shock, specific data for hydrocortisone in pediatrics are limited. The findings of this study would not only be a valuable addition to the existing stats but might also help develop a protocol for the use of hydrocortisone therapy in children with septic shock, seeking an earlier recovery from organ failure, earlier reversal of shock, and lower mortality in children with sepsis and septic shock.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DRUG	Intravenous Hydrocortisone	Children will receive early intravenous hydrocortisone at 2 mg/kg/day divided every 6 hours, continued for 7 days or until resolution of shock.
DRUG	Standard care	The children will be managed by following standard institutional treatment protocol.

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-06-30
• Completion: 2026-06-30
• First posted: 2026-01-02
• Last updated: 2026-01-02

Locations

1 site across 1 country: Pakistan